We included pre-treatment and post-treatment tumor specimens from diabetic patients exposed to GLP-1 targeting agents (GLP-1 exposed; n=7) and diabetic patients non-exposed to GLP-1 targeting agents (GLP-1 non-exposed; n=4) but otherwise matched for other clinical variables (Fig. 3A; Supplementary Table S1). This evidence concerns the gene GCG and neoplasm.